Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
1999-01-20
2001-03-13
Fitzgerald, David L. (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C435S069100
Reexamination Certificate
active
06201105
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention relates to cytokine receptors and more specifically to tumor necrosis factor receptors.
Tumor necrosis factor (TNF&agr;, also known as cachectin) and tumor necrosis factor-&bgr; (TNF&bgr;, also known as lymphotoxin) are homologous mammalian endogenous secretory proteins capable of inducing a wide variety of effects on a large number of cell types. The great similarities in the structural and functional characteristics of these two cytokines have resulted in their collective description as “TNF.” Complementary cDNA clones encoding TNF&agr; (Pennica et al.,
Nature
212:724, 1984) and TNF&bgr; (Gray et al.
Nature
312:721, 1984) have been isolated, permitting further structural and biological characterization of TNF.
TNF proteins initiate their biological effect on cells by binding to specific TNF receptor (TNF-R) proteins expressed on the plasma membrane of a TNF-responsive cell. TNF&agr; and TNF&bgr; were first shown to bind to a common receptor on the human cervical cell line ME-180 (Aggarwal et al.,
Nature
318:665, 1985). Estimates of the size of the TNF-R determined by affinity labeling studies ranged from 54 to 175 kDa (Creasey et al,
Proc. Natl. Acad. Sci. USA
84:3293, 1987; Stauber et al.,
J. Biol. Chem.
263:19098, 1988: Hohmann et al.,
J. Biol. Chem.
264:14927, 1989). Although the relationship between these TNF-Rs of different molecular mass is unclear, Hohmann et al. (
J. Biol. Chem.
264:14927, 1989) reported that at least two different cell surface receptors for TNF exist on different cell types. These receptors have an apparent molecular mass of about 80 kDa and about 55-60 kDa, respectively. None of the above publications, however, reported the purification to homogeneity of cell surface TNF receptors.
In addition to cell surface receptors for TNF, soluble proteins from human urine capable of binding TNF have also been identified (Peetre et al.,
Eur. J. Haematol.
41:414, 1988; Seckinger et al.,
J. Exp. Med.
167:1511, 1988; Seckinger et al.,
J. Biol. Chem.
264:11966, 1989; UK Patent Application, Publ. No. 2 218 101 A to Seckinger et al.; Engelmann et al.,
J. Biol. Chem.
264:11974, 1989). The soluble urinary TNF binding protein disclosed by UK 2 218 101 A has a partial N-terminal amino acid sequence of Asp-Ser-Val-Cys-Pro-, Cys-Pro-, which corresponds to the partial sequence disclosed later by Engelmann et al. (1989). The relationship of the above soluble urinary binding proteins was further elucidated after original parent application (U.S. Ser. No. 403,241) of the present application was filed, when Engelmann et al. reported the identification and purification of a second distinct soluble urinary TNF binding protein having an N-terminal amino acid sequence of Val-Ala-Phe-Thr-Pro- (
J. Biol. Chem.
265:1531, 1990). The two urinary proteins disclosed by the UK 2 218 101 A and the Engelmann et al. publications were shown to be immunochemically related to two apparently distinct cell surface proteins by the ability of antiserum against the binding proteins to inhibit TNF binding to certain cells.
More recently, two separate groups reported the molecular cloning and expression of a human 55 kDa TNF-R (Loetscher et al.,
Cell
61:351, 1990; Schall et al.,
Cell
61:361, 1990). The TNF-R of both groups has an N-terminal amino acid sequence which corresponds to the partial amino acid sequence of the urinary binding protein disclosed by UK 2 218 101 A, Engelmann et al. (1989) and Engelmann et al. (1990).
In order to elucidate the relationship of the multiple forms of TNF-R and soluble urinary TNF binding proteins, or to study the structural and biological characteristics of TNF-Rs and the role played by TNF-Rs in the responses of various cell populations to TNF or other cytokine stimulation, or to use TNF-Rs effectively in therapy, diagnosis, or assay, purified compositions of TNF-R are needed. Such compositions, however, are obtainable in practical yields only by cloning and expressing genes encoding the receptors using recombinant DNA technology. Efforts to purify the TNF-R molecule for use in biochemical analysis or to clone and express mammalian genes encoding TNF-R, however, have been impeded by lack of a suitable source of receptor protein or mRNA. Prior to the present invention, no cell lines were known to express high levels of TNF-R constitutively and continuously, which precluded purification of receptor for sequencing or construction of genetic libraries for cDNA cloning.
SUMMARY OF THE INVENTION
The present invention provides isolated TNF receptors and DNA sequences encoding mammalian tumor necrosis factor receptors (TNF-R), in particular, human TNF-Rs. Such DNA sequences include (a) cDNa clones having a nucleotide sequence derived from the coding region of a native TNF-R gene; (b) DNA sequences which are capable of hybridization to the cDNA clones of (a) under moderately stringent conditions and which encode biologically active TNF-R molecules; or (c) DNA sequences which are degenerate as a result of the genetic code to the DNA sequences defined in (a) and (b) and which encode biologically active TNF-R molecules. In particular, the present invention provides DNA sequences which encode soluble TNF receptors.
The present invention also provides recombinant expression vectors comprising the DNA sequences defined above, recombinant TNF-R molecules produced using the recombinant expression vectors, and processes for producing the recombinant TNF-R molecules using the expression vectors.
The present invention also provides isolated or purified protein compositions comprising TNF-R, and, in particular, soluble forms of TNF-R.
The present invention also provides compositions for use in therapy, diagnosis, assay of TNF-R, or in raising antibodies to TNF-R, comprising effective quantities of soluble native or recombinant receptor proteins prepared according to the foregoing processes.
Because of the ability of TNF to specifically bind TNF receptors (TNF-Rs), purified THF-R compositions will be useful in diagnostic assays for TNF, as well as in raising antibodies to TNF receptor for use in diagnosis and therapy. In addition, purified TNF receptor compositions may be used directly in therapy to bind or scavenge TNF, thereby providing a means for regulating the immune activities of this cytokine.
These and other aspects of the present invention will become evident upon reference to the following detailed description.
REFERENCES:
patent: 4935233 (1990-06-01), Bell
patent: 5116964 (1992-05-01), Capon
patent: 5155027 (1992-10-01), Sledziewski
patent: 5395760 (1995-03-01), Smith
patent: 5447851 (1995-09-01), Beutler
patent: 5478925 (1995-12-01), Wallach
patent: 5512544 (1996-04-01), Wallach
patent: 5605690 (1997-02-01), Jacobs
patent: 5610279 (1997-03-01), Brockhaus
patent: 5695953 (1997-12-01), Wallach
patent: 5712155 (1998-01-01), Smith
patent: 5945397 (1999-08-01), Smith et al.
patent: 325224 (1989-07-01), None
patent: 0394827 (1990-04-01), None
patent: 418014 (1991-03-01), None
patent: 417563 (1991-03-01), None
patent: 464533 (1991-06-01), None
patent: WO 8902922 (1989-04-01), None
patent: WO 9108298 (1991-06-01), None
Ashkenazi et al,Proc. Natl. Acad. Sci., USA, 88:10535-10539 (1991).
Capon et al,Nature, 337:525-530 (1989).
Evans et al,J. Exp. Med., 180:2173-2179 (1994).
Imamura et al,J. Immunol., 139:2989-2992 (1987).
Ishikura et al,Blood, 73:419-424 (1989).
Jones et al,Nature, 338 :225-228 (1989).
Langer et al,In: New Advances on Cytokines, Eds.
Romagnani et al, Raven Press, New York, pp. 349-354 (1992).
Lesslauer et al,Eur. J. Immunol., 21:2883-2886 (1991).
Loetscher et al,J. Biol. Chem., 266:18324-18239 (1991).
Mohler et al,J. Immunol., 151:1548-1561 (1993).
Peppel et al,J. Cell Biochem. Supp., 0(15 Part F):118 (1991).
Peppel et al,J. Exp. Med., 174:1483-1489 (1991).
Rutka et al,Int. J. Cancer Res., 41:573-582 (1988).
Smith et al,J. Biol. Chem., 262:6951-6954 (1987).
Dembic et al,Cytokine, 2:231-237 (1990).
Kohno et al,Proc. Natl. Acad. Sci., USA, 87:8331-8335 (1990).
Loetscher et al,Cell, 61:351-359
Beckmann M. Patricia
Goodwin Raymond G.
Smith Craig A.
Fitzgerald David L.
Sughrue Mion Zinn Macpeak & Seas, PLLC
LandOfFree
Tumor necrosis factor receptor polypeptides recombinant P75... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor necrosis factor receptor polypeptides recombinant P75..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor necrosis factor receptor polypeptides recombinant P75... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2478471